Team spirit is our key to success

The Versameb team consists of a number of senior experts in growth factor research, drug development and business building, complemented by a strong advisory team in all relevant aspects.

Friedrich Metzger Versameb


Prof. Dr. Friedrich Metzger, a scientist and co-founder of Versameb, has a long track record in Pharma R&D. Under his leadership as Head of Discovery Rare Diseases at Roche, a team of scientists and project leaders managed a portfolio of highly innovative development programs. He led preclinical activities for Risdiplam, an investigational medicine for spinal muscular atrophy which is currently in the market approval process. Previously, he championed a growth factor program from initiation into clinic, as well as multiple other discovery projects in neurological and neuromuscular diseases. Friedrich is also Professor in Neurobiology at the University of Freiburg, Germany, and holds a PhD degree in pharmacology from the University of Tübingen, Germany.


Dr. Isabel Ferreira joined Versameb in August 2019 as Chief Business Officer. Previously, she served Roche Partnering since 2015 as Director Global Business Development. In this role, she had broad responsibility across Pharma Business Development including strategy, search, evaluation, senior stakeholder management, leading cross-functional due diligence and negotiation teams to deal closure. Before joining Roche, Isabel served as Senior Director Business Development at Prosensa. During this time, she was instrumental in establishing transformative licensing transactions, supporting non-dilutive and private financing events, project management of Prosensa’s IPO launch at NASDAQ and supporting Prosensa’s acquisition by BioMarin. Earlier in her career, Isabel has been exposed to different aspects of the biopharmaceutical industry at Janssen-Cilag (Portugal), OctoPlus (The Netherlands) and Theravance (USA) in commercial, drug development and scientific roles. Isabel holds a Ph.D. in Biochemistry from the University of Groningen (The Netherlands) and an MBA from the Rotterdam School of Management (RSM), Erasmus University (The Netherlands).

Isabel Ferreira
Urs Breitenstein Versameb


Dr. Urs Breitenstein, an economist and co-founder of Versameb, is senior finance specialist with comprehensive experience from various assignments in companies in the life sciences sector at different maturity stages. As a partner of Hoffmann & Co AG, a Swiss M&A, valuation and CFO services company, he is acting as interim or part time CFO, business advisor or as a board member for companies and investors. In his previous roles, he served as a partner and team leader at international professional service firms (PwC, Deloitte) providing valuation, corporate finance and M&A services. He supported many large and mid-sized transactions in Switzerland and internationally both in life sciences as well as manufacturing and services. He is a graduate of the postgraduate study center of the Swiss National Bank at Gerzensee and holds a doctorate in economics from the University of Basel.


In his career Dr. Reinhard Ambros has gained broad experience in international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. He serves on the board of public and private bio-technology companies in Europe and the US. He also serves as advisor to German and Swiss Government Biotechnology Funds. Over the past 12 years Dr. Ambros built the Novartis Venture Fund to a leading corporate biotechnology fund.

Reinhard Ambros
Roger Meier


Roger Meier, co-founder of Versameb, is involved in many start-up and growth companies and projects in their set-up, team building, talent and fund sourcing, mainly but not only in the life sciences sector. He is also a co-founder of Cellestia, Elthera, Strekin, Kinarus, Aurealis, Nemis and other companies and serves in a number of boards. Roger is also founder and co-owner of Clarena Ltd., a company that supports corporates and executives in corporate finance, change management, coaching and HR. In his earlier career, he consulted mid to large sized multinational companies at Coopers & Lybrand (later PwC) in financial and risk management. Earlier on, he worked at the US investment bank Salomon Brothers Inc., a Geneva private bank in trading and started his career in Private Banking at Swiss Bank Corporation in Basel. He a finance degree from the University of Applied Sciences in Basel.


Eugene Tierney is an experienced business strategist and has held senior positions across the whole pharma value chain. He spent several years as head of global pharma business strategy with Roche, before becoming Therapeutic Area Head for Anti-infectives & Transplantation. He was later appointed Head of Neuroscience, with accountability for all aspects of discovery and early development, as well as commercialisation. He currently works as a consultant to pharma and biotech companies and is a non-executive director on the boards of a number of privately owned biotech companies.

Eugene Tierney versameb team
Arndt-Peter Schulz versameb team

Arndt-Peter Schulz
Medical Advisor

Arndt-Peter Schulz is an orthopedic surgeon and musculoskeletal expert at the University Lübeck and University Hospital Schleswig-Holstein.  His academic work focuses on clinical Research of Therapeutic devices and Pharmacologics in Musculoskeletal Conditions. Arndt Peter studied medicine at the University of Hamburg, University Hospital Eppendorf. He is a specialist physician in general surgery as well as specialist in orthopedics and traumatology. He has passed subexams in special traumatology and sports medicine. He is also a court appointed assessor in the field of orthopedics and trauma surgery in Schleswig-Holstein and North Rhine-Westphalia. As an active scientist and certified head of clinical studies (ZKS Lübeck), he has many years of experience in the design and management of clinical studies in various phases in the field of orthopedics and traumatology. Currently he is also Dean of Physiotherapy at the University Lübeck. His research in clinical science as well as  biomechanical studies has resulted in several Publications in the field of translational Orthopedics.

Christopher Ward
Scientific Advisor

Christopher Ward is a recognized expert in neuromuscular physiology. In his academic role at the University of Maryland Baltimore, his research focuses on cytoskeletal alterations as disease modifiers and therapeutic targets in skeletal muscle, heart and bone. As a co-founder of Myologica, a contract research biotech, he assists pharmas efforts in pre-clinical discovery and therapeutics.  Chris holds a Masters (M.S) in Kinesiology and Exercise Science from Virginia Tech and a Doctorate (Ph.D.) in Physiology from Virginia/Maryland Regional College of Veterinary Medicine

Chris Ward versameb team

Mark Sumeray
Medical advisor

Mark Sumeray is a physician scientist with 20 years of broad experience in the pharmaceutical, medical device and biotech industry and nine years of clinical practice focused on cardiovascular surgery and physiology. He has been a CMO in the rare diseases area for the last 7 years and has built development, medical and safety functions from the ground up, and supported business development activities and interactions with the financial community. Mark has been responsible for clinical and scientific interactions with Health Authorities globally, and for negotiations with payers. Previous experience includes senior roles at BMS, The Medicines Company and Ethicon, a J&J medical device company. Mark has degrees in medicine and physiology from University College London and is a Fellow of the Royal College of Surgeons.